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Abstract
Background: Snakebite has recently been declared a global public health emergency. Empirical data showing the true burden 
of snakebite is lacking. Treatment with specific antivenoms is considered the only cure. However, several factors have led 
to an ongoing antivenom crisis. This study offers recommendations concerning the improvement of antivenom access and 
control, by providing an overview of the factors limiting the successful implementation of international guidelines within 
the international industry and state institutions. It further investigates the reasons for the epidemiological knowledge gap 
regarding snakebites.
Methods: Data for this study was collected using surveys with closed- and open-ended questions, which allowed for 
descriptive and thematic analysis, respectively. Participants for this study were selected as follows: 46 manufacturers were 
contacted from the open-access World Health Organization (WHO) Database for antivenom producers; 23 National Health 
Authorities (NHAs) of high-burden countries were contacted; and 11 poison centers or experts were randomly contacted.
Results: In total, responses from 6/46 (13%) manufacturers, 10/23 (43%) NHAs, and 3/11 (27%) poison centers were received. 
The low response rates had a limiting effect on the coverage of this study, allowing only exploratory conclusions to be drawn. 
Based on the gathered information, a probable reason for the epidemiological knowledge gap is the low priority given to 
snakebites on public health agendas, driving interest and funding away from research in this field. As a consequence, the 
ensuing lack in funding is preventing state institutions and manufacturers from implementing international guidelines to the 
highest standards. Furthermore, manufacturers indicated that international guidelines were often not applicable in the field, 
lacking technical information and protocols. 
Conclusion: Snakebite ranks low on international public health agendas, and partially due to this low priority, NHAs have 
shown limited efforts in conducting epidemiological studies, training health workers on snakebite management and creating 
national snakebite management strategies. The lack of NHA involvement is reflected in poor access to appropriate antivenoms 
as well as a lack of antivenom regulation. Manufacturers are taking positive steps toward full implementation of international 
guidelines and are improving quality control procedures. However, in order for international guidelines to become truly useful 
in the field, more technical guidance is required. This study reflects that there is a general lack of knowledge transfer amongst 
various actors: most producers, health authorities, and experts expect increased and improved communication and guidance 
from leading international bodies. Due to the low response rates observed in this study, conclusions drawn herein are not 
representative of the global situation; yet provide an exploratory insight on the difficulties facing antivenom management.
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Implications for policy makers
• Inconsistent record keeping and incomplete hospital registers play a big role in the lack of epidemiological knowledge about snakebite. In addition to 
improving case reporting systems by health services, the burden of snakebite may be assessed for specific foci using community-based epidemiological 
studies. Patient records and death certifications must be improved (e.g. to use International Classifications of Diseases code T63.0 to certify death caused 
by snake envenoming).
• Teaching health workers the rational use and administration of antivenoms and proper snakebite identification will save lives and reduce antivenom 
waste. 
• More research must be supported. Including: developing treatments to prevent local tissue damage, clinical trials for existing antivenom products, and 
perhaps even a conceptual change in fundamental antivenom design.
• International networks for knowledge transfer must be established, or existing networks strengthened: improve communication between existing 
research groups by World Health Organization (WHO) coordination, hold a follow up conference on the WHO Guidelines.
• The addition of snake antivenoms to the WHO Prequalified Medicinal Products list could help ensure good quality, safe, and effective antivenoms for 
global use.
• Stricter international regulation of the antivenom market would prevent the export of non-efficacious products between countries and improve the 
quality of antivenom products. 
Implications for public
This study provides an overview of the current global situation of snake antivenom management. Venomous snakebites kill an estimated 100,000 people 
per year. Antivenoms are considered to be the only specific cure for snakebite envenomation. The technology for their production exists, yet appropriate 
distribution mechanisms and international knowledge transfer are lacking. This study appeals to the international public health community to renew efforts 
for a global antivenom strategy, to provide access to safe and effective antivenoms for the populations in need. 
Key Messages 
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Background
Snakebite envenomings kill one tenth as many people as 
malaria – an estimated 100,000 a year (1,2). Recently added 
to the World Health Organization (WHO) list of Neglected 
Tropical Diseases (NTDs), snakebite primarily affects poor 
rural populations in developing countries, who have limited 
access to appropriate antivenom treatment. The situation of 
snakebites, snakebite management and antivenom supply has 
been declared a global public health emergency (3). 
Snakebite is a recognized medical emergency in those parts 
of the world inhabited by venomous snakes. It generally 
affects people living in rural communities, with children and 
agricultural workers most at risk (3,4). Estimates show that 
snakebites occur most in South and Southeast Asia, in Sub-
Saharan Africa, and Latin America (2,3,5). According to 
existing studies, India suffers most from snakebite, with as 
many as 50,000 snakebites a year, resulting in up to 11,000 
deaths (5).
Incidence of snakebite fluctuates with seasonal changes, 
as climate changes influence annual cycles of agricultural 
activity (6,7). In Nigeria, for instance, as many as 70% of 
hospital beds can be occupied by victims of snakebite during 
the sowing and harvesting seasons (8). Furthermore, the 
impact of envenomings is much higher than case numbers 
suggest: an estimated 2 million Disability-Adjusted Life Years 
(DALYs) are lost per year for Sub-Saharan Africa alone, 
since the majority of victims are young, and many are left 
with permanent sequelae or incapacitating consequences of 
envenoming (3). This in turn can have a significant impact on 
local economies, as entire communities are dependent on the 
products of agricultural workers (3).
The true burden of snakebite has not been accurately 
measured using empirical studies, resulting in a substantial 
epidemiological knowledge gap in this field (2,9,10). This 
lack of empirical data has led to the negligence of snakebite 
on global health agendas, and a lack of interest in snakebite 
research, antivenom development, and financing. 
Snake antivenom immunoglobulins, obtained by immunizing 
horses with selective snake venoms, are considered the only 
specific treatment for snakebite envenoming (2). The WHO 
has estimated that 10 million vials of antivenoms are needed 
each year to control the effects of snakebite envenomings 
(3). The 46 laboratories dedicated to producing antivenoms 
are unable to meet this demand (3,11). Due to the neglected 
status of snakebites, governments and policy-makers largely 
ignore antivenoms, keeping them low on public health 
agendas and far away from national budgets (3,11). To 
improve global availability, larger laboratories require clearer 
descriptions of market sizes and needs, in order to plan long-
term manufacturing strategies (3,10).
The end of the 20th century saw a dramatic reduction in 
antivenom producers: Behringerwerke AG in Germany, 
which produced antivenoms for Africa and the Middle East, 
stopped production in the 1980s, South African producers 
have been fraught with difficulties, and CSL Australia stopped 
research activities into antivenoms, yet continues production 
only for Australian antivenoms (12). Production expenses, 
production complexity, and lack of a lucrative market largely 
drove such shutdowns. Integrating antivenom production 
into a global strategy to combat snakebites may be the key 
in preventing further reduction of producers in the 21st 
century (11,13).
The aforementioned drawbacks point to a central problem 
faced by antivenoms: access. Low production, inadequate 
distribution chains, and the need for species and region-
specific products thwart global antivenom availability 
(14–16). The result of low output and high production 
costs are antivenoms that are unaffordable to those who 
need them most. There is a global deficiency of appropriate 
antivenom supply, and the poor rural areas most burdened 
by snakebite, such as Sub-Saharan Africa and parts of Asia 
suffer most from this limited availability, resulting in poor 
treatment outcomes (8,12,17). 
A commendable step was taken with the publication of the 
WHO Guidelines on production, control and regulation of 
snake antivenom immunoglobulins in 2008 (18). However, 
possibly due to the absence of follow up meetings or updates 
since, problems in the implementation of these guidelines in 
high-burden regions have arisen. In order to combat some 
issues of access, the WHO has included snake antivenom 
immunoglobulins in the WHO Model List for Essential 
Medicines, encouraging countries to do the same and thereby 
ensuring national antivenom stocks; this has yet to show an 
increase in global access to antivenoms (11,12,14). The reasons 
behind this have not yet been thoroughly researched, creating 
a need to investigate the barriers to antivenom accessibility. 
This study focuses on the extent to which the international 
industry and state institutions have been able to implement 
and put to use the WHO Guidelines. Further emphasis is 
placed on the factors behind the epidemiological knowledge 
gap regarding snakebites, and what countries are doing to 
improve data collection. The study also identifies factors 
impeding global antivenom accessibility, and analyzes how 
manufacturers cope with stringent quality control measures, 
and increasing demand. Recommendations based on the 
research findings are provided at the end. 
Objective
The objective of the present study is to make recommendations 
concerning the improvement of antivenom access and 
control globally, by providing a clear overview of the factors 
limiting the successful implementation of WHO Guidelines 
within the international industry and state institutions. A 
second objective is to investigate the factors causing the 
epidemiological knowledge gap regarding snakebites.
Methods
Selection of participants
Study participants were selected for three stakeholder 
categories: manufacturers, National Health Authorities 
(NHAs), and poison centers or experts. Participants included 
representatives from all WHO regions. All known (N = 46) 
antivenom manufacturers were contacted based on the 
open-access WHO database of antivenom producers (19). 
NHAs from 23 high-burden countries were contacted, based 
on the attendance list of the WHO Bi-Regional Workshop 
on Production, Control, and Regulation of Antivenoms 
(2008, Jakarta), and 11 poison centers or experts from high-
burden regions were contacted. See Appendix 1 for a list 
of manufacturers contacted, and Appendix 2 for a list of 
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countries in which NHAs were contacted. 
Surveys
The surveys contained open- and closed-ended questions, 
and were designed to gather a broad range of information: 
included were questions on epidemiology, access to 
antivenoms, antivenom production, as well as WHO 
Guideline implementation. Each survey was designed to 
gather as much information as possible from the relevant 
actors (NHAs, manufacturers, and poison centers or experts), 
so as to acquire a complete overview of the situation regarding 
the knowledge surrounding snakebites as well as strategies for 
the production or distribution of antivenoms. For member 
states that were not implementing the WHO Guidelines, the 
aim was to establish the impeding factors as well as the type 
of technical support required for successful implementation. 
The surveys also required participants to list all venomous 
snake species, as well as all antivenoms produced in their 
countries to the best of their knowledge. This information 
was later crosschecked with WHO databases.
To increase survey response rate, each survey was 
accompanied by an explanatory cover letter. The 
questionnaires were made available both in French and 
English so as to increase response from francophone 
countries. Reminders were sent out to all survey recipients 
twice by email, and, following continued non-response, 
participants were called personally.
Full surveys used for this study can be found in Additional 
files 1-3.
Data analysis
Data analysis of the surveys was conducted using the EpiInfo 
statistical program, developed by the Center of Disease 
Control (CDC). This study mainly comprised exploratory and 
descriptive research, in which descriptive statistics are used 
for analysis of single variables. The closed questions required 
primarily bivariate responses, i.e. yes or no, and rating on 
a scale in one instance. The bulk of data collected in the 
surveys came from open questions in which participants were 
requested to either answer in lists, or write short responses. 
These answers were analyzed on an individual basis, checked 
for relevance to the question, as well as use of English. Since 
most of the open questions were intricately connected in 
meaning and context, all open answers were analyzed with an 
eye to the responses of the entire survey. 




Study participation from the three different actor groups: 
NHAs, manufacturers, and poison centers, varied 
considerably. Figure 1 provides an overview of the response 
rates for the different stakeholder groups.
NHAs from 23 countries were approached for participation 
in the study. The response rate came to 43.5%, meaning that 
responses from 10 countries were received. 
The 46 global manufacturers of antivenom were contacted 
using the contact information provided in the WHO online 
database (19). Unfortunately, 23 emails did not reach the 
intended participants, as their contact details were invalid, 
out of date, or simply not listed. This in itself is a sign that no 
efforts have been put into maintaining an up-to-date database. 
Out of the remaining 23 manufacturers that presumably did 
receive our emails, only seven sent back responses, leading 
to a response rate of 30% for manufacturers. The absolute 
response rate was 26%, however, because two individuals 
from the same institute provided responses; these responses 
were combined and regarded as a single entity. It is important 
to note that the manufacturer responses in this study only 
represent 13% of the total number of global antivenom 
producers. Therefore, conclusions based on these responses 
should only be made tentatively.
Poison centers or experts from 11 countries were approached 
to obtain supplementary information on snakebite and 
antivenom production in their region. Three surveys were 
sent back, resulting in a 27% response rate for this group.
However, the majority of NHAs, manufacturers, poison 
centers and even experts on the topic did not respond upon 
repeated contact over an extended period of time.
Appendix 1 and 2 provide a list of the NHAs and 
manufacturers that were contacted for this study and denotes 
study  participants.
Lack of epidemiological knowledge
NHAs were asked to rank the priority of snakebites in their 
national health agendas on a scale from 1–5. Where 1 is 
given lowest priority and 5 is the highest priority. Without 
exception, all NHAs ranked snakebites as having low priority, 
with an average grade of  1.38/5. The fact that such low 
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priority is given to snakebites in the 10 countries that partook 
in this study, may point to an underlying reason for a global 
lack of epidemiological knowledge on the topic.
Furthermore, only three countries (30%) were able to provide 
indications of snakebite incidence and mortality in their 
national setting. The cumulative incidence for these three 
countries was 38,343 bites per year. These results strongly 
support the current notion that global cases of snakebites are 
underestimated on a grand scale. 
Six (60%) of the NHAs indicated that health workers in their 
countries do not receive special training on topics regarding 
snakebite. The remaining 40% that do train their health 
workers indicated that mainly doctors and pharmacists 
receive special training on venomous animal bites, and that 
only some first aid courses cover treatment of envenomed 
patients. 
The majority (70%) of the NHAs that we surveyed indicated 
that their countries require certification for the cause of 
death of a patient. For the remaining 30% of NHAs, this 
information was missing. Although the cause of death 
needs to be certified, it is likely that most snakebites go by 
unnoticed, as health workers are not sufficiently trained in 
the identification of envenomed patients. Furthermore, even 
if snakebites are correctly identified, only four of the countries 
we surveyed indicated that snakebite cases must be reported 
to the authorities. In addition, only two countries mentioned 
having a central register in which all cases of snakebite are 
recorded. 
Approaches used to improve epidemiology
NHAs were asked whether their countries have ever 
performed any epidemiological surveys on snakebites in the 
past, and whether there are currently any efforts to improve 
epidemiological knowledge of snakebites. Of the ten NHAs 
that participated in our study, only three (30%) indicated that 
epidemiological surveys on snakebites had been performed 
in their countries. Four countries (40%) had never conducted 
epidemiological surveys, and for the remaining three (30%) 
data were missing. 
The existence of current efforts to improve epidemiological 
knowledge was also questioned, and four countries (40%) 
indicated that efforts were indeed taking place. 
Implementation of World Health Organization (WHO) 
Guidelines
One of the primary objectives of this study was to find out 
whether, and to which extent, the WHO Guidelines for 
antivenoms were being implemented in selected countries. 
Both, NHAs and manufacturers were questioned about their 
knowledge concerning the guidelines.
Pooled into one group, responses from NHAs and 
manufacturers from 15 different countries were obtained. 
In total, 86.7% (n= 13) cited being aware of the WHO 
Guidelines, and only two countries (13.3%) were not aware 
of the guidelines, see Figure 2. More importantly, eight of 
the 15 countries that participated had never implemented 
WHO recommendations, and seven said they had. Below, we 
look in detail at the results found on WHO Guidelines, and 
differentiate between NHA and manufacturer responses:
National Health Authorities (NHAs) 
Of the ten NHAs that responded to our survey, only two 
(20%) said they were unaware of the WHO Guidelines, 
and the remaining 80% indicated awareness. Interestingly, 
five (50%) responders indicated that they have national 
expert groups responsible for work surrounding the 
guidelines. However, the composition of these expert groups 
remains unclear, and it is possible that some responders 
misunderstood the question and in their answers referred to 
a general health department, or an individual snake venom 
expert known to them. 
Manufacturers
All six (100%) manufacturers who responded to the 
survey said they were aware of the WHO Guidelines. This 
may indicate that producers of antivenoms, due to their 
specialization, are more fluent in staying up to date with 
developments in their field, while NHAs might neglect topics 
that are not a priority on their agendas. Nonetheless, we 
cannot draw adequate conclusions from these responses, as 
these six manufacturers represent only 14% of the global total.
Points of implementation
National Health Authorities (NHAs) 
Eighty percent (n= 8) of NHAs indicated that they were 
aware of the WHO Guidelines. Of these, 37.5% (n= 3) said 
that they had implemented some recommendations from the 
guidelines, and the remaining 62.5% (n= 5) said they had not. 
As expected, the two NHAs who were unaware of the WHO 
Guidelines correspondingly also did not have an expert group, 
nor did they indicate guideline implementation.
The specific recommendations that have been implemented 
by countries include antivenom registration, production 
guidelines and quality control of antivenoms. Respondents 
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Figure 2. Awareness of WHO Guidelines among NHAs and manufacturers combined.
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noted that they use all sections of the guidelines to evaluate 
antivenom products prior to market authorization in their 
countries. Countries in which no recommendations had 
been implemented cited problems in their national health 
infrastructure, lack of technical knowledge to initiate own 
production of antivenoms, and irrelevance of guidelines 
according to policy-makers. Since the 10 NHAs that 
participated in this study represent only a fraction of the 
total number of high-burden snakebite countries, it remains 
unclear to which extent NHAs have been able to implement 
WHO Guidelines in their national settings.
Manufacturers
Five manufacturers (83%) indicated that they had 
implemented some of the WHO recommendations at their 
facility. Only one manufacturer cited no implementation 
of the recommendations. However, the manufacturer 
explained that they follow local Good Manufacturing 
Practice (GMP) and pharmacopoeia guidelines, which are 
often adapted using WHO GMP guidelines for biologicals 
i.e. the WHO Guidelines on snake antivenoms have not been 
specifically implemented, but the WHO machinery is well-
established and acknowledged by regulatory officers. These 
five manufacturers represent 10% of the total number of 
antivenom manufacturers, and it is unclear how successful 
other manufactures have been in adopting the WHO 
Guidelines.
Since the WHO Guidelines have been written from 
an inclusive perspective, covering many antivenom 
production methods, various facilities were already applying 
some of the recommendations. Most manufacturers 
explained that they refer to the WHO Guidelines for the 
construction of GMP production facilities, as well as 
streamlining quality control procedures and testing the 
final product. Further recommendations that different 
facilities implemented include proper documentation of 
final products, characterization of starting venom batches, 
horse immunization procedures, plasma pooling, as well as 
various in-process analyses, and sample retention schemes. 
Most manufacturers also cited being unable to comply with 
some of the WHO recommendations, as their facilities lack 
certain technical equipment, or funds to upgrade to the latest 
machines. One aspect that remains least implemented is the 
viral-validation process, as this requires highly specialized 
equipment.
Technical help required
Seven (70%) of the NHAs indicated that they would require 
external assistance for the implementation of all or some of 
the recommendations presented in the WHO Guidelines. 
Only two countries, both with very well-established 
antivenom production and management systems, indicated 
that they would not require external assistance for the 
implementation of the guidelines. For one country data 
was missing, however this specific respondent was only 
able to fill in the second half of the survey, as they were 
uninformed about all sections of the survey except for Access 
to Antivenoms. It is highly likely that this country too, is in 
need of external assistance to implement the guidelines. 
Four of the NHAs that cited requiring external assistance to 
implement WHO recommendations also provided details 
about the type of support they required: the most common 
request was for technical support to adapt WHO Guidelines 
to national settings, as well as help and funding in conducting 
training programs for regulatory officers, health workers, and 
the public, on topics surrounding snakebites. In addition, 
respondents requested support to set up or streamline 
production facilities, and support in antivenom quality control 
including the safety and efficacy of unevaluated imports. 
Further aspects in need of external assistance included: 
improved access to information, know-how, networking, 
funding for epidemiological and clinical studies, technical 
support with regards to information material (leaflets, 
posters, brochures), creating awareness for prioritizing 
antivenom use.
Interestingly, poison center/expert respondents revealed that 
they would like some kind of acknowledgement for groups 
who are providing efforts in the management of snakebites 
and antivenoms. This ties in closely with the requests for 
improved networking and knowledge transfer. Furthermore, 
respondents said that they would like direct instructions from 
WHO offices to help them initiate appropriate, and country 
specific solutions.
Compared to the NHAs, fewer antivenom manufacturers 
cited the need for external assistance to implement the 
WHO Guidelines. Nonetheless, half of the manufacturers 
did indicate the need for external guidance. Most commonly 
mentioned aspects involved the provision of specific 
technical protocols that can be followed in the field. These 
included training of staff for caprylic acid precipitation and 
plasmapheresis, consultants for viral reduction processes 
and for acquiring appropriate GMP approved equipment, 
consultants for capacity building surrounding laboratory 
animals including the use of non-equine animals, and 
consultants for the production of polyvalent antivenoms. 
In general, all manufacturers cited the need for support in 
acquiring the latest technology on antivenom production, 
the best production equipment, as well as in constructing 
appropriate production facilities. One manufacturer also 
indicated that they require guidance for appropriate, clear, 
and cost-effective package design.
Quality control of antivenoms
One of the main challenges within the global antivenom 
market is the production and trade of suboptimal antivenom 
preparations (7,12,20). Snake antivenoms are currently 
not prequalified by the WHO, allowing manufacturers to 
dispatch products as they see fit. Due to inter- and intra- 
species specificities in venom composition, a key aspect 
in antivenom quality control lies in the evaluation of the 
neutralizing capacity of antivenoms for the venoms of 
snakes in a specific country or region (7,18,20). The WHO 
guidelines provide detailed methodologies of preclinical 
efficacy tests that are necessary to ensure the neutralizing 
efficacy of antivenoms for specific snake species, however it 
is unknown whether manufacturers have been able to follow 
all these recommendations (7,18,20). The lack of national and 
international regulation of antivenoms results in suboptimal 
products being made available on the market (11). A negative 
consequence is that countries without local manufacture of 
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antivenoms purchase products, which do not match their local 
snake population. Those that end up being affected by this 
global mismanagement are the patients, whose mistreatment 
may trigger distrust in the health systems.
Quality control at production facilities
All of the manufacturers surveyed indicated having some 
sort of quality control procedure in their production 
process. All of the manufacturers also indicated having an 
external quality control department responsible for testing. 
The manufacturers stated that they follow national or 
international pharmacopoeia guidelines for good laboratory 
practices and GMP. Finally, all the final antivenom products 
produced by the facilities surveyed undergo rigorous testing 
(including Pyrogen test, potency test, abnormal toxicity, 
sterility, pH, appearance). 
In general, it appears that the manufacturers that partook 
in this study are well-equipped for quality control 
testing. In support of this claim, we also found that all 
manufacturers were subject to quality control measures 
set by national regulatory guidelines. Most manufacturers 
mentioned stringent GMP guidelines, facility requirements, 
environmental regulations, as well as packaging regulations. 
The manufacturers also indicated having to send batch 
documentation and regular quality control reports to 
NHAs. All but one manufacturer said they have to undergo 
regular inspections by NHAs, during which all GMP and 
quality system aspects, for the entire production chain are 
tested. The one manufacturer that indicated not undergoing 
regular inspection noted that they were pending application 
submissions to their FDA, and that inspections would 
commence in 2014. 
In accordance with the results received from manufacturers, 
our NHA respondents indicated that those countries with 
local manufacture of antivenoms do possess national 
regulatory guidelines, and inspect manufacturing facilities 
on a regular basis. Unsurprisingly, countries without local 
manufacture of antivenoms indicated not having any 
regulatory guidelines for the production of antivenoms.
Use of reference preparations
The creation of reference preparations for snake venoms or 
antivenoms is a topic that is widely discussed in the current 
literature, and has been recommended by the WHO on several 
occasions (12,18). Of the manufacturers that partook in this 
study, all but one indicated that they only used in-house 
reference preparations of venoms and antivenoms to ensure 
consistency of their products. One of these manufacturers 
indicated that they were in the process of nationalizing their 
in-house reference standards so that these could be used 
nationwide. The last manufacturer said that they do not 
use any reference preparations in their production process. 
Since the majority of manufacturers only test their antivenom 
batches against in-house reference preparations, it is difficult 
to compare antivenoms on a national, or even international 
level, and for buyers to get an idea of what an ideal product 
should consist of. Nonetheless, the use of in-house reference 
preparations may be a first step towards generation of national 
reference preparations (20).
In accordance with our results from the manufacturer survey, 
90% (n= 9) of the NHAs surveyed said that they had no 
national reference preparations of snake venom or antivenoms 
available, with the exception of one. These numbers come 
as no surprise, since the majority of responses came from 
countries that do not produce antivenoms locally. Yet, of the 
three responding countries that do produce antivenoms, only 
one had national reference preparations.
These results bring to light the underlying problems of lack 
of funding and low priority given to snakebite and antivenom 
research across the globe. 
Access to antivenoms
A key issue that remains in the treatment of snakebites is 
limited access to antivenoms (8,16). It is generally agreed 
upon that quick treatment of an envenomed patient with 
appropriate antivenom substantially increases rates of 
survival and reduces morbidity (14,21). Most countries with 
a high burden of snakebite do not have the infrastructure 
or market size to support local antivenom production (3). 
Furthermore, many important manufacturers have shut down 
or been privatized. As a consequence many countries still 
struggle with providing effective, appropriate, and affordable 
antivenoms for their citizens. 
Snake antivenoms as Essential Medicines
All of the countries from which we received NHA responses 
operated with an essential medicines list. Snake antivenoms 
were found on 70% (n= 7) of the national essential medicines 
lists. Two respondents cited not listing antivenoms as 
essential medicines, and one respondent did not have this 
data available. The fact that snake antivenoms are already 
found on the majority of essential medicines lists in countries 
that participated in this study, representing different WHO 
regions, is an optimistic step towards improving access to 
antivenoms. However, conclusions should only be cautiously 
drawn, as these seven countries represent a small fraction of 
those with a high burden for snakebite.
Antivenoms for different snake species
Antivenoms are not universally effective, creating a need to 
produce antivenoms for different snake immunotypes, which 
are inter- and intra-species specific (7,20). 
Only 33% (n= 2) of the manufacturer respondents indicated 
that they produce antivenoms for all medically important 
snakes in their countries. The remaining 66% (n= 4) 
indicated that they were only able to produce antivenoms for 
the medically most important snakes. Manufacturers cited 
reasons such as scarcity of venom samples, difficulties to 
breed snakes, as well as lack of funds for not being able to 
produce antivenoms for all snake species. 
All manufacturers were aware of the intra-species venom 
differences from snakes inhabiting different regions. 
Fifty percent of the manufacturers said that they produce 
antivenoms that take into account these differences in 
immunotypes. However, only one manufacturer offered an 
explanation of how they ensure that there is sufficient cross-
reactivity of their antivenom products for the different venom 
immunotypes: they sourced venom animals from across the 
species range to cover the geographical variation. At facilities 
where snakes are farmed and bred on site, it is possible that 
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effectiveness of the resulting antivenoms decreases for the 
same snake species in the wild, meaning that the potency of 
the antivenoms in real situations may become suboptimal. 
Production output and prices
There exists a wide range of antivenom producers across 
different regions: from facilities in India producing over one 
million vials a year, to small-scale, private producers in Australia, 
producing <5,000 vials a year. Most of these manufacturers 
focus on producing antivenoms for their geographical 
regions, however some also export internationally. The 
five manufactures that provided production data represent 
11% of the total number of producers worldwide, and their 
output amounts to approximately 15% of the total need 
for antivenoms. If the remaining 40 antivenom producers 
manage to produce similar total amounts, it should be 
possible to achieve the global target of 10,000,000 antivenom 
vials per year.
Moreover, antivenom prices vary across regions. The cost 
for one vial of antivenom ranged from €7.00 per vial from 
a producer in Pakistan, to €25 per vial from a producer in 
Thailand, to €1500.00 per vial from an Australian producer. 
The therapeutic price for a treatment using antivenoms can 
be up to ten times higher than the price for a single vial, as 
the severity of envenoming affects the amount of antivenom 
required. Moreover, export prices are usually 50%–200% 
higher than local prices. The huge price discrepancy between 
different producers is most likely due to the fact that those 
producers selling at low prices are heavily government 
subsidized or even government run, whereas expensive 
antivenoms are produced by privatized facilities. Although 
some of the prices for antivenoms appear low from a western 
perspective, €7 is a huge price to pay for persons living in 
poverty, or at about €1 a day.
Coping with demand
Four (66%) of the manufacturers that responded to our 
survey said that their production outputs depend on clinical 
needs of antivenoms in their countries. One manufacturer 
indicated that their production did not depend on national 
clinical needs, and one did not provide this data. Three 
(50%) of the manufacturers said that they were able to cope 
with the demand placed on them by their NHAs, two said 
they were unable to cope, and for one data was missing. 
The two manufacturers that were unable to cope with 
demand explained that they were the only producers in their 
countries, and that there were no other producers, even in the 
private sector. Fortunately, both cited that they were either 
undergoing renovations at their current facilities, or building 
new laboratories and stables to expand their output. 
Three (50%) of the manufacturers that responded to our 
surveys are large-scale producers that export antivenoms 
worldwide. The other half indicated that their facilities only 
qualified as small-scale manufacturer, and did not have 
the means, or output for international export. The three 
manufacturers eligible for international export indicated that 
they primarily exported to neighboring countries with the 
same snake species, or to zoos and institutions at which snakes 
from their countries are kept. One of the big manufacturers, 
located in India, listed several African countries as export 
destinations, yet they did not explain which antivenoms were 
exported, nor did they justify cross-reactivity. 
 
Discussion and Conclusion
It has been one hundred and fifteen years since Calmette 
successfully treated a patient with anti cobra venom (22). 
Since then, antivenom technology has advanced little, and 
a lack of interest, investments, as well as low prospects of 
commercial returns, has resulted in a global antivenom crisis 
(12). The fact that more than 100,000 people are left to die due 
to snakebite envenomings reflects a global loss of momentum 
in snakebite research, antivenom development, and financing. 
Just forty-six antivenom producers are struggling to meet the 
demand of 10 million antivenom vials per year, unsuccessfully. 
There is a fundamental flaw in the global management of 
snakebite and antivenoms, and this study tries to offer a sliver 
of explanation as to what is going wrong.
The essence of this study was to provide general information 
about where snakebite and antivenoms rank on public health 
agendas, how much is known about these topics, whether 
access to efficacious antivenoms may become a reality, and 
whether the international industry and state institutions have 
been able to implement international guidelines.
The main difficulty that was encountered during the study 
was that many intended participants were unreachable, 
due to expired contact details provided in the WHO web-
database. When trying to contact the global manufacturers of 
antivenoms, half of the emails did not go through, and from 
the remaining half that did go through; recipients were very 
reluctant to respond. This study extended over a prolonged 
period of time, during which intended participants were 
repeatedly contacted by different means, and encouraged to 
send their responses. It is a fact that the majority of recipients, 
already involved in snakebite or antivenom research, 
refused to participate. If this non-response is due to lack of 
interest, the continuation of this apathetic behavior will only 
exacerbate problems in the long run. Due to the low response 
rates encountered in this study, the coverage of the results 
presented here is not universally applicable to the global 
situation of antivenom management. Nonetheless, the results 
provide focused empirical data that verify what others have 
discussed before; the lack of momentum and resources made 
available to combat this neglected disease (12,13,17).
In the course of this research, it quickly became clear that there is 
an absence of empirical data of the global snakebite burden. The 
results indicate that a probable reason for the epidemiological 
knowledge gap is the low priority given to snakebites on 
public health agendas. Unfortunately, high priority is unlikely 
to be given to a disease lacking epidemiological data, and 
epidemiological studies for low priority issues are unlikely 
to be funded. Furthermore, the majority of countries that 
partook in this study do not train their health workers 
specifically about snakebite management, nor do they require 
snakebites to be reported to authorities. The surveys showed 
that snakebite management in most participating countries is 
patchy at best. An applauded achievement lies in the recent 
addition of snakebite to the WHO list of NTDs, which may 
garner increased attention and perhaps even funding from 
the international community (7,13).
The findings in this study verify the notion of a global 
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antivenom crisis; they are still largely inaccessible to those 
who need them most, and often traded inefficiently (8). Even 
when available, selling prices of a single vial of antivenom far 
exceed the income of those living at or near the poverty line, 
and that is disregarding the fact that several vials are required 
for successful treatment. The results clearly indicate that 
privatization, and small production output drive up prices to 
unrealistic amounts, and it appears that only heavy subsidies 
can outweigh these costs. 
The respondents to our manufacturer surveys were very 
limited. It is highly likely that the results obtained from such 
a low response rate are not applicable to all manufacturers, 
and should not be applied to the global situation. It is 
largely understood that the 46 manufacturers of antivenoms 
worldwide are not able to cope with global demand (12). Well-
established institutions are making serious efforts to improve 
antivenom supply in their regions, but are unable to tackle the 
global crisis without increased international collaboration. 
Nevertheless, the manufacturers that partook in this study 
were located in countries with a range of economical 
backdrops, allowing for certain conclusions to be drawn. 
The findings point out that unequal resource allocation 
may be causing the inequality of antivenom supply i.e. that 
producers focus their production on antivenoms for snake 
species found in their vicinity, and may not have the resources 
available to produce antivenoms against snakes from other 
regions. This unequal resource allocation seems to be one of 
the main driving forces hindering the access to appropriate 
antivenoms. The region suffering most from this resource 
inequality is Africa, which continues to receive inappropriate 
antivenoms from foreign manufacturers (17). 
A major problem that may result from the continued 
distribution of suboptimal antivenoms is that patients may 
lose trust in antivenom treatment methods. Simply put, if 
snakebite victims keep getting treated with inappropriate 
antivenoms and as a result die or suffer permanent sequelae, 
their families and friends may not believe that antivenoms 
are indeed effective. As a result, this could lead to a reversal 
of advancements seen in public health, and could even spill 
over to other treatment methods. It is likely that patients may 
want to seek out traditional healers instead (2). With an eye 
to this problem, several survey respondents suggested that 
antivenoms should be added to the WHO Prequalification of 
Medicinal Products Program, which would ensure that NHAs 
could purchase safe, effective and quality controlled products 
for their citizens.
A positive step towards quality global antivenom production 
was made with the publication of the WHO Guidelines (18). 
A major part of this research was to determine whether the 
guidelines have been implemented in the countries surveyed. 
What we found was that all manufacturers, we contacted were 
well aware of the WHO Guidelines, and that the facilities had 
already been using many of the recommended methods. More 
importantly, some of the facilities that partook in this study 
were contributors to the WHO Guidelines. All manufacturers 
indicated that they referred to the recommendations for 
the construction of GMP laboratories, and for streamlining 
quality control testing procedures on the final product. 
Nonetheless, not all manufacturers had been able to 
implement all of the recommendations, primarily due to a 
lack of exact manufacturing protocols or facility blueprints. 
Furthermore, most manufacturers cited financial restraints 
and lack of technical personnel to interpret and implement 
guidelines in national settings. Importantly, the existence of 
in-house quality control procedures or adherence to GMP 
guidelines, does not guarantee the production of efficacious 
antivenom products. Antivenom production requires vigorous 
preclinical testing that surpasses standard laboratory quality 
control measures, and takes into account the paraspecific 
neutralization levels for species-specific venoms (7). 
An important consideration made in the WHO Guidelines 
concerned the establishment of international reference 
preparations for venoms and antivenoms. Our results show 
that only one participating country is on the path to creating 
national reference preparations, whereas the majority let 
producers use in-house reference standards. It will not 
be easy to create international reference standards for 
antivenoms due to the immunological differences in venom 
composition, however if countries manage to create national 
reference pools for each medically important snake species, 
that could eventually lead to an international stock of global 
reference standards, which can be used for further tests and 
assessments (18). 
The NHAs reflected less technical knowledge about 
the WHO Guidelines, despite the presence of specific 
recommendations for national regulatory authorities 
such as those regarding distribution, management and 
control. Although 80% of the NHA respondents said they 
were aware of the guidelines, it is unclear to which extent 
recommendations have been implemented on governmental 
levels, as descriptions were scarce. Furthermore, 80% in this 
study only represents 8 countries in the world, which is a 
fraction of those burdened by snakebite worldwide. It appears 
that the WHO Guidelines have primarily been adopted in 
the antivenom production community, and remain largely 
disregarded on official levels. It appears that NHAs deem the 
WHO Guidelines to be irrelevant in their work, as the title 
attracts a more technical crowd, and may deter policy-makers. 
One issue that was mentioned repeatedly outside of the scope 
of the survey questions was the lack of knowledge transfer 
amongst institutions involved in snakebite or antivenom 
research and production. From a public health perspective, 
it is only beneficial for producers to mediate their own 
discussions and to actively provide technical assistance to 
less experienced producers. Lack of knowledge seems to be 
a recurring theme in the study of snakebites and antivenoms; 
on the one side we have policies obstructing progress, and 
on the other we have a free market economy that is creating 
unreasonable competition.
Almost seven years have gone by since the WHO Guidelines 
were published, and the document has not been updated. How 
is it that snakebite mortality accounts for one tenth as much 
mortality as malaria, but that there exists no global snakebite 
strategy that is comparable to global malaria strategies? 
Similarly, a global fund could be started for the procurement 
of antivenoms, which are then dispatched globally. Most of the 
current antivenom producers are also producers of vaccines, 
and there is no doubt that contacts to funders and distributers 
exist. With this backdrop, it only seems appropriate for the 
WHO to initiate a coordinated approach that will connect the 
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scattered dots.
Snakebite is treatable. The means to reduce morbidity and 
mortality exist. A much stronger international initiative is 
needed to focus the attention of international organizations, 
government agencies, research institutes, and funders on 
snakebites and antivenoms. 
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Appendix 1
List of manufacturers contacted, as listed in the WHO database for antivenom producers
No. Country Manufacturer name Comments
1 Algeria Institut Pasteur d'Algerie Invalid contact
2 Argentina Instituto Biologico Argentino "BIOL" Invalid contact
3 Argentina Instituto Nacional de Produccion de Biologicos No response
4 Argentina Laboratorio Central de Salud Publica Invalid contact
5 Australia CSL Limited Responded
6 Bolivia Instituto Nacional de Laboratorios de Salud Invalid contact
7 Brazil Centro de Producao e Pesquisas de Immunobiol Invalid contact
8 Brazil Fundacao Ezequiel Dias (FUNED) Invalid contact
9 Brazil Instituto Butantan No response
10 Brazil Instituto Vital Brazil S.A. Invalid contact
11 China Lanzhou Institute of Biological Products Responded
12 China Shanghai Institute Biological Technology Co., Ltd. Invalid contact
13 Colombia Laboratorios PROBIOL S.A. No response
14 Costa Rica Instituto Clodomiro Picado Invalid contact
15 Croatia Immunoloski Zavod Invalid contact
16 Ecuador Instituto Nacional de Higiene y Medicina Tropical "Leopoldo Izquieta Pérez" Invalid contact
17 Egypt VACSERA No response
18 France Sanofi-Pasteur No response
19 India Bharat Serums & Vaccines No response
20 India Biological E Limited Invalid contact
21 India Haffkine Biopharmaceutical Corporation Ltd Invalid contact
22 India VINS Bioproducts Ltd Responded
23 Indonesia BioFarma No response
24 Iran Razi Vaccine & Serum Research Institute Invalid contact
25 Japan Japan Snake Institute No response
26 Japan The Chemo-Sero-Therapeutic Research Institute (Kaketsuken) Invalid contact
27 Korea Korea Vaccine Co. Ltd. No response
28 Mexico Instituto Bioclon No response
29 Mexico Instituto Nacional de Higiene (Birmex) No response
30 Myanmar Myanmar Pharmaceutical Factory No response
31 Pakistan National Institute of Health Responded
32 Peru Instituto Nacional de Salud. Centro Nacional de Productos Biológicos Invalid contact
33 Philippines Biologicals Manufacturing Division (Research Institute for Tropical Medicine) Responded
34 Poland BIOMED (Wytwornia Surowic i Szczepionek) No response
35 Russia Federal State Company for Immunobiological Medicines “Microgen” Invalid contact
36 Saudi Arabia National Antivenom & Vaccine Production Center (NAVPC) No response
37 Serbia Institute of Virology, Vaccine and Sera TORLAK No response
38 South Africa South African Vaccine Producers (SAVP) No response
39 Taiwan National Institute of Preventive Medicine Invalid contact
40 Thailand Queen Saovabha Memorial Institute Responded
41 Tunisia Institut Pasteur de Tunis No response
42 Uruguay Instituto de Higiene Invalid contact
43 USA Protherics Inc Invalid contact
44 USA Wyeth Invalid contact
45 Venezuela Centro de Biotecnologia Invalid contact
46 Vietnam Institute of Vaccines and Biological Substances (IVAC) Invalid contact
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Appendix 2
List of National Health Authorities (NHAs) contacted (country name 
only), based on attendance list of the WHO Bi-Regional Workshop on 
Production, Control, and Regulation of Antivenoms (2008, Jakarta)
No. Country Comment
1 Benin No response
2 Bangladesh No response
3 Brazil No response
4 Burkina Faso Responded
5 Cambodia Responded
6 China No response
7 Egypt No response
8 Ethiopia No response
9 Indonesia No response
10 Iran No response
11 Japan Responded
12 Kenya No response
13 Malaysia Responded
14 Nepal Responded
15 Niger No response
16 Nigeria Responded
17 Philippines No response
18 Saudi Arabia No response
19 Tanzania No response
20 Thailand Responded
21 Uganda Responded
22 Vietnam Responded
23 Zimbabwe Responded
